Maged Shenouda bought $97k of RLMD
Chief Financial Officer at RELMADA THERAPEUTICS, INC.. 200,000 shares at an average of $0.49, traded May 16, 2025, filed May 20, 2025.
Score components
- +22RoleCFO
- +10Trade size$97k at market
- +10Relative to holdingsHoldings up 226%
- +8Price context87% below the 52-week high
- +15Cluster4 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +17.3%, 3m +4.0%, 6m +615.2%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001213900-25-046087, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 16, 2025 | POpen-market purchase Common Stock | +50,000 | $0.44 | $22k | 138,335 | May 20, 2025 |
| May 19, 2025 | POpen-market purchase Common Stock | +90,000 | $0.49 | $44k | 228,335 | May 20, 2025 |
| May 20, 2025 | POpen-market purchase Common Stock | +60,000 | $0.52 | $31k | 288,335 | May 20, 2025 |
Related signals
Other insiders at RELMADA THERAPEUTICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 59Moderate | RELMADA THERAPEUTICS, INC. | Sergio Traversa Chief Executive Officer | $828k 200,000 shares | +15% | |
| 59Moderate | RELMADA THERAPEUTICS, INC. | Maged Shenouda Chief Financial Officer | $844k 200,000 shares | +25% | |
| 42Moderate | RELMADA THERAPEUTICS, INC. | Maged Shenouda Chief Financial Officer | $48k 11,665 shares | +1% | |
| 48Moderate | RELMADA THERAPEUTICS, INC. | Sergio Traversa Chief Executive Officer | $113k 27,500 shares | +2% | |
| 63Notable | RELMADA THERAPEUTICS, INC. | Chuck Ence CAO and COO | $299k 136,000 shares | +51% | |
| 57Moderate | RELMADA THERAPEUTICS, INC. | Paul Edward Kelly Chief Operating Officer | $198k 90,000 shares | +22% | |
| 76Notable | RELMADA THERAPEUTICS, INC. | Maged Shenouda Chief Financial Officer | $1.1M 500,000 shares | +173% | |
| 74Notable | RELMADA THERAPEUTICS, INC. | Sergio Traversa Chief Executive Officer | $600k 272,500 shares | +27% | |
| 51Moderate | RLMDbuy RELMADA THERAPEUTICS, INC. | Sergio Traversa Chief Executive Officer | $178k 265,976 shares | +36% | |
| 58Moderate | RELMADA THERAPEUTICS, INC. | Chuck Ence CA and CO | $103k 228,961 shares | +588% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.